What is your company doing to optimize optionality and long-term value in every stage of your company’s life? It may be prudent to familiarize yourself with all the different options and steps in business development. Collaboration with big corporates should be considered as part of your strategy. In fact, a recent publication by Melchner von Dydiowa, Van Deventer and Couto in Nature Biotechnology1 suggested that formal ties to pharma strongly correlate with startup success at the clinical as well as preclinical stage.
In this break-out session we will discuss some of the fundamentals of business development, which may help you successfully manage the collaboration and partnership process. During the session we will touch upon topics such as:
· Overview of the Business Development Process
· Presenting data in partnering discussions
· Due Diligence
· Negotiations
This break-out session is geared towards innovators interested in collaborations with big corporates in pharma and medtech.
Powered by:
Speakers
Since 2020 Niels has been leading Innovation Activation for Johnson & Johnson Innovation – JLABS in the Netherlands, leveraging the strong footprint the Johnson & Johnson Family of Companies has in the country. Activations are aligned closely to local life sciences ecosystem initiatives and stakeholders.
Niels has been with Johnson & Johnson since 2015 when he joined as communications manager for Janssen Infectious Diseases & Vaccines R&D. He supported the leadership team in roles of increasing responsibilities, including internal communications, external communications and change communications.
Before joining Johnson & Johnson, Niels worked for agency Hyphen Projects, which is specialized in events and publications in life sciences. He helped organize events such as Innovation for Health, BCF Career Event and BioBusiness Summer School.
Tess joined the Johnson & Johnson Innovation team as an External Innovation Scout for the Benelux region. Within this role she focuses on the sourcing, screening and evaluating opportunities and potential matches between internal and external research needs of high strategic value to Johnson & Johnson Innovation.
Tess pursued her PhD at the Netherlands Cancer Institute in Amsterdam to study epigenetic processes in cancer progression. This research exposed her to the latest genomic technologies, which led her to a Postdoc at the Hubrecht institute working on a technology to detect epigenetic signatures in single cells. After this, she extended her network in the biotech industry with her previous role as a Business Development Director at the oncology startup iClusion.
Powered by: Hyphen Projects | Connect | Join Global Investor Forum | |||
Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 VAT no: NL8184.34.491.B01 |
| Register here
|
© Copyright 2023 by Hyphen Projects